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Open Forum Infectious Diseases
MAJOR ARTICLE

Validation of Apolipoprotein A-1 and Fibronectin
Fragments as Markers of Parasitological Cure for
Congenital Chagas Disease in Children Treated With
Benznidazole
Elizabeth Ruiz-Lancheros,1,2 Asieh Rasoolizadeh,1,2 Eric Chatelain,3 Facundo Garcia-Bournissen,4 Samanta Moroni,4 Guillermo Moscatelli,4
Jaime Altcheh,4 and Momar Ndao1,2

Background. No reliable tests or validated biomarkers exist to ensure parasitological cure following treatment of Chagas disease
(CD) patients chronically infected with Trypanosoma cruzi. As seroreversion, the only marker of cure, happens more quickly in children, we investigated the correlation between previously identified biomarkers and seroreversion in children.
Methods. Thirty CD children (age 1 month to 10 years) diagnosed as T. cruzi positive (time point S0) were treated with benznidazole (BZ) 5–8 mg/kg/d for 60 days. At least 2 serological tests were used to evaluate treatment efficacy from the end of treatment (S1) until seroreversion (S2). Thirty children (age 1 month to 10 years) and 15 adults were used as healthy controls (HCs).
Immunoblot and a proteomic-based assay were used to validate previously identified fragments of apolipoprotein A-1 (ApoA1) and
fibronectin (FBN) as CD biomarkers.
Results. Correlation between seroreversion and absence of ApoA1 and FBN fragments by immunoblot was observed in 30/30
(100%) and 29/30 (96.6%) CD children, respectively. ApoA1 and FBN fragments were absent at the end of BZ treatment in 20/30
(66.6%) and 16/30 (53.3%) children, respectively. Absence of fragments in serum profiles was confirmed by mass spectrometry.
Using intact protein analysis, a 28 109-Da protein identified as full-length ApoA1 by tandem mass spectrometry was detected in HC
serum samples.
Conclusions. These data confirm that ApoA1 and FBN fragments can discriminate between healthy and T. cruzi–infected samples. Correlation with seroreversion was shown for the first time; results suggest predictive capacity potentially superior to serology,
making them potentially useful as surrogate biomarkers.
Keywords. apolipoprotein A-1; biomarkers; Chagas disease; children; fibronectin; test of cure.

Chagas disease (CD), caused by the protozoan parasite
Trypanosoma cruzi, is the most neglected tropical disease in
Latin America [1, 2]. It is estimated that 8 million people are
infected worldwide [3]. Vector-mediated transmission by triatomine bugs occurs in rural and suburban areas in Central
and South America. In nonendemic countries, CD is no longer
an exotic disease but has become an increasing public health
concern [4]. This is the result of population migration, vertical transmission, organ transplantation, and blood transfusion,
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resulting in a high percentage of chronic asymptomatic patients
in these populations [2, 5, 6].
Currently, there are no reliable tests or validated biomarkers
to ensure parasitological cure in chronically infected patients.
Polymerase chain reaction (PCR) techniques lack sensitivity
when parasitemia is low and do not guarantee parasitological cure [7, 8]. Serological tests cannot discriminate between
treated individuals and those with CD and have shown inconsistent results in adult studies [9]. Blood bank evaluations rely
on serological testing, and confirmation assays must be performed to elucidate the status of non-negative results [10, 11].
In addition, seroreversion, the gold standard, can take decades
in adults. This is a major barrier to determining the optimal
treatment duration for currently available drugs or the assessment of potential new drugs in proof-of-concept clinical trials
[12–15]. Clearly, there is an urgent need for reliable biomarkers
[12, 13].
Of all the parasite biomarkers proposed over the last decade
(reviewed in [13, 14, 16]), very few, if any, have been validated
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and 10 years old, born in Argentina, mainly infected by vertical transmission, and whose mothers were from Argentina,
Bolivia, or Paraguay and were not treated before or during
pregnancy. CD children <6 months were diagnosed by positive T. cruzi parasitemia (microhematocrit and PCR), serological tests (enzyme-linked immunosorbent assay [ELISA] and
indirect hemagglutination antibody test [IHA]; Wiener Lab,
Rosario, Argentina). Older children were diagnosed only by
serological tests. PCR was performed as described by Duffy
et al. [27]; serological tests were chosen for diagnosis and
prognosis following Argentinian guidelines. CD children were
treated with 5–8 mg/kg/d BZ for 60 days. BZ treatment efficacy in infants younger than 8 months was evaluated by parasitemia (microhematocrit and/or PCR) and serology at the
end of BZ treatment. Older children were evaluated by PCR
and serology. All children were followed up and evaluated by
serology every 3 months during the first year post-treatment
and then every 6 months until 2 consecutive negative serological results. Children were considered cured when at least
2 serological tests were negative, as recommended by the
World Health Organization (WHO). For the proposes of this
study, only children who reached seroreversion were included.
Cardiac involvement due to CD was determined by electrocardiogram (ECG) and echocardiogram at diagnosis and every
year after treatment. Thirty children within the same age range
were used as healthy negative controls for serology, mass spectrometry analysis, and immunoblot. Samples from 10 infected,
untreated mothers and 15 uninfected adults were evaluated
using the same serological tests and included as positive controls and negative controls for immunoblots, respectively.

METHODS

Rabbit antisera against the predicted neo-termini of a 24.7-KDa
ApoA1 fragment and a 28.9-KDa fibronectin fragment were
generated and used in immunoblots as described by Santamaria
et al. [18]. Briefly, 1-μL serum samples were separated in
4%–12% Novex Bis-Tris Midi gradient gels (Life Technologies,
Carlsbad, CA) under reducing conditions and transferred onto
nitrocellulose membranes. Membranes were blocked in 5%
milk-0.05% Tween-20 in phosphate buffer saline and incubated
overnight at 4°C with rabbit anti-ApoA1 (24.7) 1:500 or rabbit
anti-FBN (28) 1:1000 dilution. Then, they were incubated for
1 hour at room temperature with horseradish peroxidase-conjugated antirabbit IgG (GE Healthcare Life Sciences, Uppsala,

Ethical Statement

The protocol of this study was approved by the Ethical Boards
for Medical Research of the Hospital de Niños Ricardo
Gutierrez, Buenos Aires, Argentina (approval number CEI
14/14, institutional ethical committee). Written consent was
required from patients’ legal representatives and was obtained
from all patients or legal guardians, as appropriate.
Study Design and Setting

The cohort study took place at the Hospital de Niños
R. Gutierrez. The study included children between 1 month
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Sample Collection

Serum samples were collected in tubes without anticoagulant,
centrifuged, and aliquoted for serological tests, immunoblot
assay, and proteomics analysis. All samples were stored at –20°C
within 1 hour of collection. Aliquots for each subject at diagnosis
(S0), end of BZ treatment (S1), and seroreversion (S2) were sent
to the National Reference Center for Parasitology (Montreal,
Quebec) for immunoblotting and proteomics analysis.
Immunoblot Analysis
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and can be used to determine treatment efficacy. Using a proteomic platform to compare serum protein profiles of asymptomatic chronically infected CD patients and healthy controls,
we identified different host biomarkers [17]. Candidate biomarkers were further evaluated in a cohort of adult patients
treated with nifurtimox (Nfx) and followed up for 3 years [18].
Among these, the most promising candidates were apolipoprotein A-I (ApoA1) and fibronectin (FBN) fragments, which
were significantly upregulated in chronic or asymptomatic CD
subjects compared with healthy controls (HCs) and returned to
levels similar to those seen in HCs 3 years after Nfx treatment.
Immunoblot assays for some of these proteomics-derived biomarkers were successfully developed and used to assess parasitological cure after Nfx treatment [18].
Our unexpected discovery prompted us to study T. cruzi–host
interactions further. Indeed, several lines of evidence suggest
that T. cruzi can take up low-density lipoprotein (LDL) particles, can be found in adipose tissue (a potential reservoir site of
the parasite in man), and use LDL receptors during cell invasion, which leads to the increased accumulation of LDL cholesterol in host tissue in both acute and chronic CD [19–23]. In
addition, truncated forms of ApoA1 have been shown to result
from the digestion of native ApoA1 in high-density lipoproteins
(HDLs) by cruzipain, a T. cruzi cysteine protease, in vitro and
in vivo [24, 25]. Computational studies suggest that n-terminal
and c-terminal ApoA1 peptides are important for its lipid association to form HDL particles [26]; however, the effect of ApoA1
truncations in HDL metabolism remains to be studied.
These findings suggest that ApoA1 fragments, among others,
could be valid indicators of parasite signature and promising
biomarkers to assess cure in Chagas patients. Taking advantage
of the more rapid seroreversion in children (a few months to a
few years), we investigated if the absence and/or reduction of
ApoA1 and FBN fragments correlated with seroreversion in a
cohort of children treated with benznidazole (BZ) and followed
until seroreversion. This correlation, which has been impossible in adult samples, confirmed these fragments as signatures
of parasite clearance and, consequently, validated them as biomarkers of parasitological cure.

Sweden) 1:100 000 dilution. Bands were developed by chemiluminescence using SuperSignal West Pico (Pierce, Rockford, IL)
and exposed to x-ray film. Antibody specificity to new n-termini fragments was demonstrated by the detection of recombinant proteins of the respective fragments and the absence of
detection of full-length proteins.
Serum Fractionation and Profiling

ApoA1 Full-Length Identification by LC–Tandem MS

To establish the ApoA1 full-length identity in HCs, precursor
ions for masses similar to full-length ApoA1 were submitted
for a second analysis using a tandem mass spectrometry (MS/
MS) acquisition method. MS/MS spectra were submitted to
Bruker Daltonics BioTools 3.2 SR4 software (Bruker, Bellirica,
MA) for protein identification using the Mascot Search Engine
server, version 2.2.4 (Matrix Science, London, UK). Spectra
were searched against human databases (Uniprot) with the following parameters: top-down analysis, no enzymatic digestion,
and peptide and fragment tolerance set to 15 ppm and 0.05 Da,
respectively.

Patients

All CD patients were asymptomatic with no cardiac involvement or other Chagas-associated pathology at enrollment. BZ
treatment was well tolerated with mild adverse events [28].
Table 1 shows the sociodemographic and clinical characteristics
of the 60 children included in the study. The parasitology and
serology results at diagnosis (S0), end of BZ treatment (S1), and
seroreversion (S2) are summarized in Supplementary Table 1.
All children included in the study showed negative parasitemia
by microhematocrit and/or PCR at S1 and remained negative
until S2. ELISA and IHA titers were reduced or negative at S1
compared with S0 (Supplementary Table 1); titers continued to
decrease until S2. Serological test results showed discrepancies
(Supplementary Table 1), as observed in other studies [9, 10];
thus, children were only considered cured when at least 2 tests
were negative, as recommended by the WHO.
Immunoblot of 24.7-KDa ApoA1 and 28.9-KDa FBN Fragments in Sera

ApoA1 and FBN digestion by cruzipain generates new
N-termini fragments. Accordingly, antibodies against
neo-peptides will recognize the protein fragments but not
their full lengths, even if they are polyclonal antibodies; this
specificity is demonstrated in Figure 1. When comparing
infected (CD child) and noninfected samples (HC child and
HC adult), the antisera selectively detected ApoA1 (24.7)
(Figure 1A) and FBN (28.9) (Figure 1B) fragments in samples from CD children, whereas no band corresponding to
the sizes of the fragments or full-length proteins was detected
in HC children and adults, supporting previous observations
[18]. Additionally, antibodies recognized specifically the
Table 1. Sociodemographic and Clinical Characteristics of 30 CD Child
Patients and 30 HC Children

Age at diagnosis

Sex
Origin

CD children

HC children

1 mo

7

None

2–11 mo

11

15

>1 y

12

15

Female

15

15

Male

15

15

Buenos Aires

22

N/A

Entre Rios

1

Capital Federal

7

Infection route

Congenital

28

Unknown

2

Origin of mother

Argentina

14

Bolivia

13

Paraguay

2

Benznidazole treatment
(5–8 mg/kg/d)

Unknown

1

60 d

22

<60 d

5

>60 d

3

Abbreviations: CD, Chagas disease; HC, healthy control.
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High-throughput serum fractionation by ion exchange chromatography was performed using a ProteinChip serum fractionation kit (Bio-Rad, Hercules, CA) as described by Ndao
et al. [17]. All transfers and incubations were performed in an
automatized liquid handling station (Biomek FX, BeckmanCoulter, Brea, CA). Our previous studies [17, 18] show that
biomarkers of 28.9 and 24.7 KDa were present in fractions 1
(pH 9) and 3 (pH 5), respectively. These fractions were further
analyzed using liquid chromatography–mass spectrometry
(LC-MS).
Serum fractions were desalted, dried, and reconstituted in
30 µL of water–0.1% formic acid (FA) for mass spectrometry
intact proteins analysis using a Maxis ESI/Q-TOF mass spectrometer (Bruker, Bellirica, MA) coupled with uHPLC (Dionex
Ultimate 3000 RSLC nano-HPLC, Thermo Fisher Scientific,
Waltham, MA). In brief, 5 µL of each fraction was loaded onto
a C4 analytical column (5 µm–300 Å, 150*1 mm; Phenomenex,
Torrance, CA). Proteins were separated on a linear gradient of
5%–90% of solvent B at a flow rate of 175 µL/min. Solvent A was
water–0.1% FA, and solvent B was acetonitrile–0.8% FA.
Continuous mass spectra during the chromatogram run were
acquired in MS mode between 400 and 3000 m/z. Scan speed
was set at 1 Hz and ESI at 4200 V – N2 7l/min – 220°C. Data
files were analyzed using Compass Data Analysis 4.3 Software
(Bruker, Bellirica, MA). Profiles from CD and HC children were
compared using Bruker Compass Profile Analysis 2.1 software
(Bruker, Bellirica, MA). An ANOVA t test model and a principal component analysis model were generated to identify peaks
significantly different between HC and CD groups. Maximum
entropy deconvolution was used to calculate protein peak
masses for the biomarkers of 24.7 and 28.9 KDa discovered in
our previous studies [17, 18].

RESULTS

HC Adult

KDa
260
160

HC Child

FL R

CD Child

HC Adult

HC Child

KDa

B
CD Child

A

FL R
FBN FL

40
30
20

FBN
Fragment
with tag

30

ApoA1 FL
ApoA1
Fragment
with tag

corresponding fragments in infected mothers (Supplementary
Figure 1) and did not show reactivity with any of the HC children and adults (not shown).
Using the immunoblot described above, ApoA1 and
FBN fragments were undetected at S2 in all (30 of 30 samples; 100%) and 29 of 30 (96.6%) CD children, respectively.
However, the only specimen (child of 9.9 years) that was FBN
positive was very faint. Interestingly, ApoA1 and FBN fragments were undetected by immunoblot at S1 in 20 children
(66.6%) and 16 children (53.3%), respectively (Figure 2), who
remained seropositive at this point. In some children, the
band intensity of fragments at S1 was reduced as compared

2.8Y
kDa

S0 S1 S2

7M

4M

S0 S1 S2 S0 S1 S2

10M

1M

with S0 (children of 4 months for ApoA1 and 10 months for
FBN) (Figure 2).
Profiling Analysis of Serum Proteins

To confirm the immunoblot results and further emphasize the
potential of ApoA1 24.7-KDa and FBN 28.9-KDa fragments as
biomarkers of cure for CD, serum protein profiles were determined by mass spectrometry. Additionally, we searched for
proteins corresponding to full-length ApoA1 in CD and HC
children. Upon MS data analysis, proteins of around 28 KDa
were detected at 38.5 minutes of the liquid chromatography
gradient in HC samples. The peak 827.7288 m/z, which predicts

2.8Y

1M

S0 S1 S2 S0 S1 S2 S0 S1 S2

kDa

S0 S1 S2

7M

4M

S0 S1 S2 S0 S1 S2

10M

1M

1M

S0 S1 S2 S0 S1 S2 S0 S1 S2

40
30

20

20

Figure 2. Immunoblot analysis of apolipoprotein A-1 (24.7) and fibronectin (28.9) fragments in serum samples from Chagas disease (CD) children at different time points.
Serum from CD children age >1 year and younger were collected at diagnosis (S0), end of treatment (S1), and at seronegative conversion (S2). Immunoblot analysis was
performed on 1 uL of serum using polyclonal antibodies against neo-peptides PALEDL and PFTDV from APOA1 24.7-KDa and FBN 28.9-KDa fragments, respectively.
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Figure 1. Immunoblot analysis of ApoA1 (24.7) and FBN (28.9) fragments in CD and HC. Each antiserum detects expected bands in a CD child but not in child or adult
HCs. The specificity of the rabbit anti-ApoA1 (24.7) serum (A) and rabbit anti-FBN (28) (B) for the corresponding fragments is demonstrated by their inability to detect native
full-length proteins, ApoA1 (~28.1 KDa) and FBN (~220 KDa), while reacting with 6xHis tag recombinants of the 24.7-KDa ApoA1 and 28.9-KDa FBN (migration at ~35 KDa)
fragments, respectively. Abbreviations: ApoA1, apolipoprotein A-1; CD, Chagas disease; HC, healthy control; FBN, fibronectin; FL, full-length; R, recombinants.

samples but undetected in HC at the same retention times
(Supplementary Figure 2), which strongly suggests that these
fragments are upregulated in CD and correspond to the ApoA1
and FBN fragments that were identified in our previous studies
[17, 18].
The same peaks were searched for in serum fractions of CD
children at the different time points in the study. For this, the
CD serum samples were pooled according to the immunoblot

a mass of 28 109 Da, was present in the extracted ion chromatogram of HCs and statistically upregulated in HCs compared
with CD patients (P = .03617) (Figure 3A). A second MS acquisition for the precursor ion in HC confirmed that the protein
corresponds to full-length ApoA1 (Figure 3B).
CD and HC serum fractions 1 and 3 were analyzed by MS
and searched for peaks corresponding to the molecular weight
of ApoA1 and FBN fragments. Peaks were present in CD

A
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Figure 3. A, Volcano plot for all proteins identified in serum sasmples of Chagas disease (CD) and healthy control (HC) children. Mass of 28 109 Da, eluted at 38.5 minutes
of the liquid chromatography gradient, (red point) is significatively upregulated in HC compared with CD. B, Tandem mass spectrometry spectra of 28 109 Da mass precursor
peak and Biotools results that confirm the apolipoprotein A-1 identity.
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results. As observed in Figure 4, the masses corresponding
to the ApoA1 fragment (24 756 Da) and the FBN fragment
(28 786 Da) were undetected at S2, whereas the mass corresponding to full-length ApoA1 (28 093 Da) was detected. As
was observed by immunoblot, the detection of the ApoA1
24.7-KDa mass was reduced at S1 compared with its intensity at S0 (Figure 4A). In contrast, the intensity of full-length
ApoA1 increases at S1 and S2 compared with its intensity
at S0 (Figures 4 and 5). The fragments were undetected by
MS in serum samples that were immunoblot negative at S1
(Figure 5).
DISCUSSION

A
Intens.

F3S0Pool 5ul inj_BB6_01_402.d: +MS, 40.42–41.21min, -Peak Bkgrnd, Deconvoluted (MaxEnt, 703.19–1139.62, *0.0892857, 35 000), Smoothed (0.36,4,GA), Smoothe

F3–S0
3000

24 756.7733

2000

28 094.5816

1000

0

F3S1Pool 5ul inj_BD6_01_403.d: +MS, 40.51–41.51min, -Peak Bkgrnd, Deconvoluted (MaxEnt, 697.93–1301.96, 0.1, 5000), Smoothed (0.40,4,GA), Smoothed (0.40,4

F3–S1

1250

24 757.4544

1000
750

28 097.2217
500
250

0
×105
1.50

F3S2Pool 5ul inj_BD6_01_404.d: +MS, 39.87–41.31min, Deconvoluted (MaxEnt, 524.37–1872.97, *0.0892857, 35 000), Smoothed (0.36,4,GA), Smoothed (0.36,4,GA)

F3–S2

1.25

28 078.4727

1.00
0.75
0.50
0.25
0.00
20 000

22 000

24 000

26 000

28 000

30 000

32 000

34 000 m/z

Figure 4. Representative mass spectrometry spectra of biomarkers 24.7 (A) and 28.9 (B) for samples from Chagas children patients treated with benznidazole. Proteins of
24 756 and 28 786 Da are present at diagnosis (S0), the intensity of 24 756 Da is reduced after treatment (S1), and both biomarkers are no longer detected at seroreversion
(S2). A peak of 28 078 Da corresponding to apolipoprotein A-1 (~28.1 KDa) is detected at seroreversion.
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Confirmation of parasitological cure during the chronic stage
of Chagas disease is still challenging. Current diagnostic tools

have limitations, can lead to inconsistent results, and cannot
measure cure rates without decades of follow-up [29–31]. This
lack of suitable tests of parasitological cure and treatment efficacy assessment is the biggest challenge in CD prognosis and
drug research and development.
In our last 2 cohort studies [17, 18], we presented the first
proteomic approach to identifying diagnostic biomarkers for
Chagas disease using top-down proteomics. We demonstrated
that highly sensitive and specific host biological markers were
able to distinguish asymptomatic CD adult patients from HC in
2 different populations [17, 18]. ApoA1 fragments of 24.7, 13.6,
and 9.1 KDa, as well as a 28.9-KDa FBN fragment, were upregulated in asymptomatic CD adults and returned to levels similar
to those seen in HCs after 3 years of Nfx treatment. However, all
adults were still seropositive at 3-year follow-up, and it was not

B
Intens.
4000

39.40–40.75min, Deconvoluted (MaxEnt, 506.36–1049.75, *0.107 143, 35 000), Smoothed (0.32,10,GA)
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Figure 4.

28 961.7923
27 000

28 000

29 000

30 000

31 000

32 000

m/z

Continued

possible to compare our biomarker results with seroreversion,
which is currently the gold standard of parasitological cure.
In the current study, taking advantage of the quicker serological conversion in children compared with adults, we collected
serum samples of CD children at diagnosis, end of BZ treatment, and seroreversion. BZ treatment is well tolerated in children [28], and in the present study, all children were followed
periodically after treatment until 2 serological tests were negative. This was the perfect scenario for comparing the presence or
absence of previously identified biomarkers with seroreversion
and validating their use as biomarkers of parasitological cure.
Using both immunoblot and MS, we observed that ApoA1
(24.7-KDa) and FBN (28.9-KDa) fragments were present in
Argentinian CD children, but not in HCs. MS analysis also
showed that full-length ApoA1 protein was statistically upregulated in HC children and its abundance increased in serum
from CD children after treatment and at seroreversion. This
pattern is consistent with those seen in our previous studies
with Bolivian and Venezuelan samples [17, 19], which demonstrates the reproducibility of our approach across the South
American population, an important factor considering the

variety of infective T. cruzi strains in patients in these regions.
This reproducibility was also achieved using different proteomics platforms, reinforcing the robustness of our data.
These fragments were absent in samples from CD children
treated with BZ and considered cured as determined by seroreversion. To our knowledge, this is the first time that a correlation has been established between the presence/absence of a
newly identified marker and seroconversion in Chagas disease.
Potential CD biomarkers have been studied in CD children
during the early chronic indeterminate stage. Soluble platelet
selectin (sP-selectin) and soluble vascular cell adhesion molecule–1 (sVCAM-1) titers decreased in 66.7% and 41% of the
children treated with BZ compared with controls [32]. Equally,
interferon-γ profiles and M2 muscarinic receptor autoantibody
(anti-M2R AAb) were decreased 6 months after BZ treatment.
Anti-M2R AAb reactivity declined to between 29.7% and 88.1%
of the initial level [33]. Specific cellular surface markers associated with a type 1–modulated cytokine pattern were elevated
after BZ treatment in a different study [33]. However, none of
these biomarkers has been further studied and/or shown correlation with seroconversion.
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Figure 5. Mass spectrometry spectra of biomarkers 24.7 (A) and 28.9 (B) for children’s samples that show negative immunoblot results at the end of benznidazole (BZ)
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